18F-Prostate-Specific Membrane Antigen PET/CT Imaging for Pancreatic Cancer (PANSCAN-2)
Study Overview
This study explored the use of 18F-PSMA PET/CT imaging to detect potentially resectable pancreatic cancer, specifically pancreatic ductal adenocarcinoma (PDAC). Current imaging methods struggle to distinguish between cancerous and non-cancerous pancreatic conditions and often miss lymph node metastases.
Study Details
Seventeen patients with resectable PDAC underwent 18F-PSMA PET/CT scans before surgery. The scans were analyzed to measure how much the cancerous tissue absorbed the tracer, using metrics like the maximum standardized uptake value (SUVmax) and tumor-to-background ratio (TBR).
Key Findings
- Out of 17 scans, 13 showed positive tracer uptake.
- The average SUVmax was 5.0, indicating some level of detection.
- The average TBR was 3.3, suggesting the primary tumor was identifiable.
- However, no tracer uptake was found in lymph node or distant metastases.
- The correlation between PET scan results and tissue PSMA expression was not significant.
Conclusions
While 18F-PSMA PET/CT can detect some pancreatic cancers, its effectiveness is limited. The uptake was generally low and not specific to PDAC, with no uptake in metastatic sites.
Trial Registration
This trial is registered as PANSCAN-2 in the European Clinical Trials Database (EudraCT number: 2020-002185-14).
Enhancing Clinical Practice
Clinical trials are essential for developing safe and effective treatments. To integrate these benefits into everyday practice, our AI-driven platform, DocSym, consolidates clinical standards and research into an accessible resource for healthcare providers.
Streamlining Healthcare Operations
In today’s healthcare landscape, efficiency is key. Our mobile applications facilitate scheduling, treatment monitoring, and telemedicine, simplifying patient care management.
Improving Patient Outcomes
By leveraging AI, clinics can optimize workflows, enhance patient outcomes, and reduce reliance on paper processes. Discover more about our solutions at aidevmd.com.
